Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Theravance (NASDAQ: TBPH) sets 2039 generic date in YUPELRI patent settlement
Theravance Biopharma, Inc. announced a settlement of patent litigation concerning its YUPELRI® (revefenacin) inhalation solution with Mankind Pharma. This agreement grants Mankind Pharma a royalty-free, non-exclusive license to sell a generic YUPELRI in the U.S. beginning April 23, 2039. The resolution clarifies the long-term exclusivity of YUPELRI and eliminates legal uncertainties, though it is subject to review by U.S. antitrust authorities.